Selvi Durmus Erim

List of Publications by Year
in descending order

23	1,001	566801 15	676716 22
papers	citations	h-index	g-index

23	23	23	1754
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	MicroRNAs, macrocontrol: Regulation of miRNA processing. Rna, 2010, 16, 1087-1095.	1.6	229
2	Oral Availability and Brain Penetration of the B-RAF^{V600E} Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar. Molecular Pharmaceutics, 2012, 9, 3236-3245.	2.3	113
3	Apical ABC Transporters and Cancer Chemotherapeutic Drug Disposition. Advances in Cancer Research, 2015, 125, 1-41.	1.9	83
4	Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699). Pharmaceutical Research, 2015, 32, 37-46.	1.7	79
5	Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b. Cancer Research, 2015, 75, 2729-2736.	0.4	59
6	Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). Pharmaceutical Research, 2015, 32, 2205-2216.	1.7	53
7	Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer. Oncogene, 2018, 37, 2251-2269.	2.6	49
8	The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice. Drug Resistance Updates, 2016, 27, 72-88.	6.5	46
9	In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters. International Journal of Cancer, 2014, 135, 1700-1710.	2.3	43
10	Cationic Pd(II)/Pt(II) 5,5-diethylbarbiturate complexes with bis(2-pyridylmethyl)amine and terpyridine: Synthesis, structures,DNA/BSA interactions, intracellular distribution, cytotoxic activity and induction of apoptosis. Journal of Inorganic Biochemistry, 2015, 152, 38-52.	1.5	41
11	P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387. Pharmacological Research, 2013, 76, 9-16.	3.1	38
12	Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drugâ€“Drug Interactions in Vivo. Molecular Pharmaceutics, 2015, 12, 4259-4269.	2.3	32
13	P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice. Clinical Cancer Research, 2014, 20, 3133-3145.	3.2	29
14	Liquid chromatographyâ€“tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma. Biomedical Chromatography, 2014, 28, 1366-1370.	0.8	22
15	P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice. Molecular Pharmaceutics, 2015, 12, 3714-3723.	2.3	20
16	Liquid chromatographyâ€“tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 889-890, 144-147.	1.2	14
17	Liquid chromatographyâ€“tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 626-629.	1.4	14
18	Liquid chromatographyâ€“tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 925, 124-128.	1.2	12

#	Article	IF	Citations
19	Liquid chromatographyâ€“tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 934, 22-25.	1.2	10
20	Liquid chromatographyâ€“tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 895-896, 174-177.	1.2	9
21	Analysis of 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and Its Phase I and Phase II Metabolites in Mouse Urine Using LCâ€“UVâ€“MSâ€“MS. Chromatographia, 2011, 74, 215-226.	0.7	4
22	Liquid chromatographyâ€“tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N+-glucuronide in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 895-896, 169-173.	1.2	2
23	Abstract 4419: The role of ABC transporters in PhIP-induced colon carcinogenesis. , 2012, , .		0